Biotech

ASCO Abstract Preview: ImClone, Genentech

05/08/08 - 06:59 AM EDT


In order to help prepare for the annual meeting of the American Society of Clinical Oncology, better known as ASCO, I've compiled a cheat sheet of significant cancer research abstracts.

Use these abstract numbers and titles to search the ASCO Web site on May 15, starting at 9 p.m. EDT. That's when the cancer research group will be posting the full content of the annual meeting research abstracts online.

This is the first time ASCO has made research abstracts freely available to everyone in advance of its annual meeting, which runs May 31 through June 3. In years past, of course, many of these abstracts, often containing important and potentially market-moving clinical data, have leaked to well-connected Wall Street investors and traders.

That has led to volatile trading in cancer-related biotech stocks in advance of the ASCO meeting. Whether trading volatility ramps up or down this year with abstracts available to everyone remains to be seen. With the list I've put together, however, you should be ready.

Before we get to the list of significant abstracts, here are a few notes:

The ASCO Web site can be found at www.asco.org, where the annual meeting abstracts will be made available in the Annual Meeting Program Online.

As I've warned in the past, ASCO is keeping abstracts for plenary sessions and certain late-breaking presentations under wraps until the start of the meeting. Most importantly, this means that Erbitux results from the FLEX lung cancer study will not be available on May 15. That means ImClone Systems IMCL investors will just have to wait a little while longer.

Previous «
1 2 3 4 5 6 7
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Headlines & Perspectives

Biotech

Go To Section Home


05/05/08
Discovery Labs Holds Out Hope for Surfaxin

The stock Monday regains some of its sharp Friday losses on the company's positive response to FDA delays. But is the reaction overly optimistic?


05/03/08
Feuerstein's Biotech-Stock Mailbag

Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.


05/02/08
FDA Approval Delay Sinks Discovery Labs

Surfaxin receives an approvable letter, but the additional delays that accompany it send shares plummeting in premarket trading.


04/28/08
Cramer's Take on the Top 10 Searched Stocks

Apple and AT&T were among the most searched stocks on TheStreet.com Friday. Here's what Cramer had to say about them recently.


04/26/08
Jim Cramer's Best Blogs

Catch up on his thinking on the hottest topics of the past week.


04/26/08
Coming Week: Make or Break

Investors will have to deal with a Fed meeting and another flood of earnings and economic data.


04/27/08
This Week's Barron's Roundup

Looking for deep value with Defiance Asset Management, polling big investors about where the market's headed, plus much more.


04/28/08
Monday's Analysts' Upgrades, Downgrades

See who made what calls.


02/29/08
3 Stocks I Saw On TV

3 Stocks I Saw On TVDan Fitzpatrick examines three stocks viewed on Fast Money and Mad Money Today's stocks include Deere & Co., Petrobras and MBIA


04/28/08
One Bank Pick Stumbles, the Other Soars

TheStreet.com Ratings checks in on First Community Bancorp and First Niagara Financial Group two months after recommending the stock.


04/28/08
Grand Theft Auto IV Hits the Jackpot

Take-Two's latest hit receives a perfect score from industry reviewers.


Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Premium Stock Ideas
Access Action Alerts Plus to find out Cramer’s latest picks now!